Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 98

Results For "NIT"

6333 News Found

Govt. of Madhya Pradesh, mlHealth360 launch AI radiology pilot in 10 district hospitals
Digitisation | April 09, 2026

Govt. of Madhya Pradesh, mlHealth360 launch AI radiology pilot in 10 district hospitals

At the center of deployment is mlHealth360’s proprietary Scaida AI platform, designed to detect and triage abnormalities in CT scans


University of Leeds launches landmark HALO study on lifelong impact of childhood blood disorders
Hospitals | April 09, 2026

University of Leeds launches landmark HALO study on lifelong impact of childhood blood disorders

Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust


Dr. Jitendra Singh urges industry to step up R&D collaboration
R&D | April 09, 2026

Dr. Jitendra Singh urges industry to step up R&D collaboration

Minister highlights RDI fund, private participation in space and nuclear sectors, and calls for faster reforms to improve ease of research in India


Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio
Biotech | April 09, 2026

Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio

The acquisition complements Gilead’s existing oncology expertise and development infrastructure


India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters
Drug Approval | April 09, 2026

India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters

In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga


Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity
Drug Approval | April 08, 2026

Aurobindo gets USFDA approval for Dapagliflozin with 180-day exclusivity

Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size


Alkem enters daily wellness space with launch of 'A to Z Daily' multivitamin
Healthcare | April 08, 2026

Alkem enters daily wellness space with launch of 'A to Z Daily' multivitamin

New adult supplement combines 26 vitamins, minerals and botanicals to address stress, energy, immunity and cognitive wellness in one daily tablet


Zydus gets USFDA final approval for generic Dapagliflozin with 180-day shared exclusivity
Drug Approval | April 08, 2026

Zydus gets USFDA final approval for generic Dapagliflozin with 180-day shared exclusivity

Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility